FIGURE 2.

Screening of biomarker candidates and confirmation of CD147 and A33 on fEVs and tissues. (a) Procedures for screening biomarker candidates. (b) Western blotting analysis of fEVs from CRC patients and healthy donors (left) and the relative band intensity (right). (c) Schematic of immunogold labelling to confirm CD147 and A33 on fEVs. (d) Representative IG‐TEM pictures of CD63, CD147, and A33 labelled by 10 nm‐gold on fEVs. fEVs without primary antibody treatment were used as control. Scale bar: 100 nm. (e) Immunofluorescence (red) of CD147 and A33 in colorectal carcinoma (CRC) and para‐carcinoma (N) tissues. Scale bar: 50 μm